World Journal of Urology

, Volume 36, Issue 2, pp 321–322 | Cite as

Management of biochemically recurrent prostate cancer: molecular imaging perspective

Letter to the Editor
  • 69 Downloads

Notes

Compliance with ethical standards

Conflict of interest

The author declares that they have no conflict of interest.

References

  1. 1.
    Toussi A, Stewart-Merrill SB, Boorjian SA et al (2016) Standardizing the definition of biochemical recurrence after radical prostatectomy—what prostate specific antigen cut point best predicts a durable increase and subsequent systemic progression? Urology 195(6):1754–1759CrossRefGoogle Scholar
  2. 2.
    Bouchelouche K, Tagawa ST, Goldsmith SJ et al (2011) PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med 41(1):29–44CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Giesel FL, Kesch C, Yun M et al (2017) 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin Genitourin Cancer 15(3):e497–e499CrossRefPubMedGoogle Scholar
  4. 4.
    Martinez-Lorca A (2016) The challenge of adequate metastasis detection in the patient with castration-resistant prostate cancer. Rev Mex Urol 76:129–130CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Nuclear Medicine DepartmentRamon y Cajal University HospitalMadridSpain

Personalised recommendations